Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.77 |
| ▸ | NPC1 | O15118 | 6/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.77 |
| ▸ | MEN1 | O00255 | 2/20 | 0.77 |
| ▸ | HPGD | P15428 | 1/20 | 0.77 |
| ▸ | SCD5 | Q86SK9 | 8/20 | 0.70 |
| ▸ | SCD | O00767 | 4/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17553956 | 0.86 | NPC1 (1.00) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL21536247 | 0.82 | SCD5 (1.00) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL16373565 | 0.81 | RAB9A (0.76) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL21536464 | 0.80 | SCD5 (0.69) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL9911613 | 0.80 | RAB9A (0.77) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL21523640 | 0.80 | SCD5 (1.00) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL21536514 | 0.80 | NPC1 (0.78) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL21535961 | 0.79 | SCD5 (0.74) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL21535960 | 0.77 | SCD5 (0.72) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL21536519 | 0.77 | KMT2A (0.88) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3784234-A1 | COMPOUNDS AND USES THEREOF | Yumanity Therapeutics, Inc. (US) | 2021-03-03 | — | — | EP | disclosed |
| US-10919885-B2 | Compounds and uses thereof | YUMANITY THERAPEUTICS, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| US-10919885-B2 | Compounds and uses thereof | YUMANITY THERAPEUTICS, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| US-20190330198-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-31 | — | — | US | disclosed |
| US-20190330198-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10919885-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | RAB9A 2129/4885NPC1 72/4885SMN1; SMN2 13/4885 |
| US-20190330198-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | RAB9A 2129/4885NPC1 72/4885SMN1; SMN2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.